Immunotherapies with immune checkpoint inhibitors (ICIs), such as anti-programmed cell death-1 (PD-1) antibodies (nivolumab and pembrolizumab) [155,156,157] and anti-programmed cell death ligand 1 (PD-L1) antibodies (atezolizumab) [158] have greatly improved the survival of patients with advanced HCC due to chronic HBV or HCV infections. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.